Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

70.32
Delayed Data
As of Jun 27
 -0.29 / -0.41%
Today’s Change
51.82
Today|||52-Week Range
75.12
+2.22%
Year-to-Date
BMY Regular Dividend: BMY will begin trading ex-dividend on 06/29/16 with a $0.38 dividend payable to shareholders of record as of 07/01/16.
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
Cramer: Let's Put Brexit in Its Historic Context
Jun 22 / TheStreet.com - Paid Partner Content
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Jun 22 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
7 Profitable Medical Stocks Ranked as Buys Now
Jun 21 / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
3 Ways This $30 Billion Market Is Bristol's for the Taking
Jun 21 / MotleyFool.com - Paid Partner Content
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Jun 22 / Zacks.com - Paid Partner Content
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Jun 21 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close70.61
Today’s open70.39
Day’s range70.09 - 71.13
Volume7,477,388
Average volume (3 months)6,078,050
Market cap$117.9B
Dividend yield2.16%
Data as of 06/27/2016

Growth & Valuation

Earnings growth (last year)-22.50%
Earnings growth (this year)+25.84%
Earnings growth (next 5 years)+21.20%
Revenue growth (last year)+4.29%
P/E ratio75.1
Price/Sales6.97
Price/Book8.22

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.68+1.77%
NVONovo Nordisk-0.15-0.29%
GSKGlaxoSmithKline-0.66-1.62%
ABBVAbbVie-1.18-1.97%
Data as of 06/27/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.66
Annual revenue (last year)$16.6B
Annual profit (last year)$1.6B
Net profit margin9.45%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs